Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-VSP02 · 2 trials · 1 indication
Patients remain on treatment until disease progression or an adverse event. Adverse events are assessed throughout treatment.
| Name | Type | Description |
|---|---|---|
| ALN-VSP02 | DRUG | The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study |
Inclusion Criteria: 1. Patient has completed a previous ALN-VSP02 study, and is deemed to have stable disease or better. 2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. 3. Patient has adequate hematologic, liver, and renal function. Exclusion Criteria: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ALN-VSP02 is an investigational drug being developed for the treatment of solid tumors with liver involvement. It is intended for patients with advanced solid tumors, as studied in clinical trials. The drug is administered intravenously and is currently in Phase 1 clinical development.
ALN-VSP02 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ALNY. The company has conducted clinical trials to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALN-VSP02 in patients with advanced solid tumors.
ALN-VSP02 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total enrollment of 48 patients. The drug is investigational and has not been approved by regulatory authorities. It remains in clinical development for the treatment of solid tumors.
ALN-VSP02 has been studied in two completed Phase 1 clinical trials. The first trial, NCT00882180, was a dose escalation study in 41 patients with advanced solid tumors with liver involvement. The second trial, NCT01158079, was an extension study in 7 patients who responded to ALN-VSP02 treatment. Both trials were conducted in the United States and Spain.
ALN-VSP02 is administered intravenously, as indicated in the clinical trial protocols. The drug was given to patients with advanced solid tumors with liver involvement in a dose escalation study to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.